Omkar Speciality Chemicals reported zero revenue for the quarters ending June, September, and December 2025. The company is in a post-NCLT approval revival phase, with significant losses continuing.
Omkar Speciality Chemicals Navigates Post-Resolution Revival with Zero Revenue
Omkar Speciality Chemicals has reported zero revenue for the quarters ending June 30, September 30, and December 31, 2025. Despite the National Company Law Tribunal (NCLT) approving the resolution plan on July 31, 2025, the company remains in a transitional phase with significant losses. ## What just happened The company's financial results for the nine months and respective quarters of 2025 show no revenue generation. Losses for the nine months ended December 31, 2025, stood at ₹125.62 lakh. The latest quarter ending December 31, 2025, recorded a loss of ₹32.84 lakh. ## Why this matters Zero revenue indicates that the operational restart following the NCLT approval is still in its very nascent stages. The continued losses highlight the financial challenges the company faces even after the resolution plan's approval and fund infusion. ## The backstory Omkar Speciality Chemicals has been undergoing a Corporate Insolvency Resolution Process (CIRP). The NCLT's approval of the resolution plan marks a critical step towards revival, with a total resolution amount of ₹26.65 crore planned for creditors and capital expenditure. ## What changes now Management has transitioned from the Resolution Professional to a new Board of Directors. Key changes include the appointment of a new CEO, Dipak Kumar Shaw, and the formation of new board committees. A new current account has been approved with ICICI Bank to support operations. ## Risks to watch Auditors have issued a qualified conclusion due to the company's CIRP status and uncertainties regarding its ability to continue as a 'going concern'. This signals ongoing financial instability. ## Peer comparison As the company is in a revival phase post-insolvency, direct peer comparison on operational metrics is not currently meaningful. Focus remains on its internal turnaround progress. ## Context metrics (time-bound) The resolution plan was approved on July 31, 2025. The Resolution Applicant has infused ₹15.08 crore up to December 2025. Payments to creditors total ₹23.14 crore, with ₹3.51 crore allocated for capex and working capital. ## What to track next Investors should closely monitor the company's progress in resuming operations, generating revenue, and improving its financial performance in subsequent quarters. The effective utilization of infused capital for operational restart is crucial.
Get stock alerts instantly on WhatsApp
Quarterly results, bulk deals, concall updates and major announcements delivered in real time.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
